Connection
Jennifer Trujillo to Peptides
This is a "connection" page, showing publications Jennifer Trujillo has written about Peptides.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.486 |
|
|
|
-
Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes Metab. 2018 11; 20(11):2690-2694.
Score: 0.408
-
Trujillo JM, Goldman J. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes. Pharmacotherapy. 2017 Aug; 37(8):927-943.
Score: 0.379
-
Goldman J, Trujillo JM. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2017 Nov; 51(11):990-999.
Score: 0.376
-
Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018 May; 130(4):365-374.
Score: 0.099
-
Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Mar; 49(3):351-9.
Score: 0.079
-
Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
Score: 0.078
-
Anderson SL, Trujillo JM, McDermott M, Saseen JJ. Determining predictors of response to exenatide in type 2 diabetes. J Am Pharm Assoc (2003). 2012 Jul-Aug; 52(4):466-71.
Score: 0.067